Truist downgraded Inspire Medical (INSP) to Hold from Buy with a price target of $125, down from $190. The firm was braced for a guidance cut, but it was bigger than expected and a lower EPS outlook reduces the stock valuation floor, the analyst tells investors in a post-earnings note. A third Inspire V delay raises execution issues amid other potential headwinds, including GLP1 trialing, coming competition and constrained capacity, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical downgraded to Neutral from Overweight at JPMorgan
- Inspire Medical downgraded to Sector Weight from Overweight at KeyBanc
- Inspire Medical Systems Reports Q2 2025 Financials
- Closing Bell Movers: Palantir hits record highs on beat and raise
- Inspire Medical Systems Reports Q2 2025 Financial Results